Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Long-Term Investments (2025)

Evommune (EVMN) has disclosed Long-Term Investments for 1 consecutive years, with $67.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments changed N/A to $67.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.5 million, a N/A change, with the full-year FY2025 number at $67.5 million, changed N/A from a year prior.
  • Long-Term Investments was $67.5 million for Q4 2025 at Evommune.
  • In the past five years, Long-Term Investments ranged from a high of $67.5 million in Q4 2025 to a low of $67.5 million in Q4 2025.